🚀 VC round data is live in beta, check it out!

Ocugen Valuation Multiples

Discover revenue and EBITDA valuation multiples for Ocugen and similar public comparables like Cormedix, Prime Medicine, Aclaris Therapeutics, Zevra Therapeutics and more.

Ocugen Overview

About Ocugen

Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, Inhaled Mucosal Vaccine Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").


Founded

2000

HQ

United States

Employees

95

Website

ocugen.com

Financials (LTM)

Revenue: $3M
Net Income: ($69M)

EV

$624M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Ocugen Financials

Ocugen reported last 12-month revenue of $3M.

In the same LTM period, Ocugen generated had net loss of ($69M).

Revenue (LTM)


Ocugen P&L

In the most recent fiscal year, Ocugen reported revenue of $4M and EBITDA of ($60M).

Ocugen is unprofitable as of last fiscal year, with EBITDA margin of (1366%) and net margin of (1537%).

See analyst estimates for Ocugen
LTMLast FY202320242025202620272028
Revenue$3M$4M$6M$4M$4M
EBITDA($60M)($65M)($53M)($60M)
EBITDA Margin(1366%)(1074%)(1302%)(1366%)
EBIT Margin(1858%)(1426%)(1086%)(1350%)(1426%)
Net Profit($69M)($68M)($63M)($54M)($68M)
Net Margin(1968%)(1537%)(1045%)(1333%)(1537%)
Net Debt$10M

Financial data powered by Morningstar, Inc.

Ocugen Stock Performance

Ocugen has current market cap of $609M, and enterprise value of $624M.

Market Cap Evolution


Ocugen's stock price is $1.80.

Ocugen share price increased by 4.0% in the last 30 days, and by 115.3% in the last year.

Ocugen has an EPS (earnings per share) of $-0.20.

See more trading valuation data for Ocugen
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$624M$609M4.0%4.0%-1.1%115.3%$-0.20

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Ocugen Valuation Multiples

Ocugen trades at 178.5x EV/Revenue multiple, and (10.4x) EV/EBITDA.

See NTM and 2027E valuation multiples for Ocugen

EV / Revenue (LTM)


Ocugen Financial Valuation Multiples

As of May 2, 2026, Ocugen has market cap of $609M and EV of $624M.

Ocugen has a P/E ratio of (8.9x).

LTMLast FY202320242025202620272028
EV/Revenue178.5x141.4x103.4x153.9x141.4x
EV/EBITDA(10.4x)(9.6x)(11.8x)(10.4x)
EV/EBIT(9.6x)(9.9x)(9.5x)(11.4x)(9.9x)
P/E(8.9x)(9.0x)(9.7x)(11.3x)(9.0x)
EV/FCF(10.9x)(8.6x)(13.7x)(10.9x)

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Ocugen Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Ocugen Margins & Growth Rates

Ocugen decreased revenue by 62% but net profit grew by 4% in the last fiscal year.

In the most recent fiscal year, Ocugen reported EBITDA margin of (1366%) and net margin of (1537%).

See estimated margins and future growth rates for Ocugen

Ocugen Margins

Last FY202420252026202720282029
EBITDA Margin(1366%)(1302%)(1366%)
EBIT Margin(1426%)(1350%)(1426%)(4137%)
Net Margin(1537%)(1333%)(1537%)(4238%)
FCF Margin(1295%)(1123%)(1295%)

Ocugen Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth(62%)(33%)9%(62%)
EBITDA Growth(19%)14%
EBIT Growth10%(16%)15%10%
Net Profit Growth4%(14%)26%4%
FCF Growth(37%)26%

Data powered by FactSet, Inc. and Morningstar, Inc.

Ocugen Operational KPIs

Ocugen's revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $0.7M for the same period.

Access forward-looking KPIs for Ocugen
LTMLast FY202320242025202620272028
Revenue per Employee$0.0M
Opex per Employee$0.7M
G&A Expenses to Revenue760%625%530%658%625%
R&D Expenses to Revenue1168%901%656%792%901%
Opex to Revenue1526%1186%1450%1526%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Ocugen Competitors

Ocugen competitors include Cormedix, Prime Medicine, Aclaris Therapeutics, Zevra Therapeutics, Supriya Lifescience, Luzhu Biotech, Sutro Biopharma, TTY Biopharm, Tempo Scan Pacific and Abclon.

Most Ocugen public comparables operate across Biopharmaceuticals, BioTech and DeepTech.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Cormedix2.0x2.0x3.1x3.6x
Prime Medicine119.5x58.9x(2.8x)(2.9x)
Aclaris Therapeutics67.1x77.5x(7.5x)
Zevra Therapeutics4.4x3.9x4.7x(16.3x)
Supriya Lifescience8.1x6.5x20.4x19.3x
Luzhu Biotech17.9x(27.2x)(157.1x)
Sutro Biopharma4.5x5.8x(3.3x)(3.3x)
TTY Biopharm2.6x2.5x7.1x

This data is available for Pro users. Sign up to see all Ocugen competitors and their valuation data.

Start Free Trial

Ocugen Funding History

Before going public, Ocugen raised $14M in total equity funding, across 2 rounds.


Ocugen Funding Rounds

DateStageRaised FromRaisedValuationRev. MultipleDeal Summary
Jun-17Series BAbdi Ibrahim Pharmaceuticals; Frank Leo; John Zhang; Lancaster Group$8MOcugen is a biopharmaceutical company based in Malvern, Pennsylvania developing treatments for sight-threatening diseases. The company closed a $7.5 million Series B funding round in June 2017 co-led by Abdi Ibrahim, a Turkish pharmaceutical company, and JSC Lancaster Group, a diversified holding company based in Kazakhstan, with participation from existing investors Frank Leo and John Zhang. The capital was designated to support advancement of the company's pipeline of potential sight-saving ophthalmology products into clinical trials. Ocugen's pipeline included OCU100 being developed for retinitis pigmentosa, OCU200 for wet age-related macular degeneration, and OCU300 for ocular graft versus host disease.
Dec-16Series AAhsan M. Nasratullah; Bernhard Hampl; EB5 Life Sciences$6M

Ocugen M&A Activity

Ocugen has acquired 1 company to date.

Last acquisition by Ocugen was on September 30th 2019. Ocugen acquired Histogenics for undisclosed valuation.

See M&A valuation multiples

Latest Acquisitions by Ocugen

Histogenics
Description
Histogenics was a Waltham-headquartered leader in musculoskeletal regenerative medicine focused on cartilage repair. Its NeoCart implant combines autologous cartilage cells with a bovine collagen scaffold for knee defects. The platform integrates tissue engineering and bioadhesives for orthopedic applications. After Phase 3 trials, the company faced challenges and filed for bankruptcy in 2019, with assets acquired by Sobi.
HQ CountryUnited States
HQ City
Boston, MA
Deal Date30 Sep 2019
Valuationundisclosed
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all Ocugen acquisitions and their M&A valuation multiples.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Ocugen

When was Ocugen founded?Ocugen was founded in 2000.
Where is Ocugen headquartered?Ocugen is headquartered in United States.
How many employees does Ocugen have?As of today, Ocugen has over 95 employees.
Who is the CEO of Ocugen?Ocugen's CEO is Shankar Musunuri.
Is Ocugen publicly listed?Yes, Ocugen is a public company listed on Nasdaq.
What is the stock symbol of Ocugen?Ocugen trades under OCGN ticker.
When did Ocugen go public?Ocugen went public in 2014.
Who are competitors of Ocugen?Ocugen main competitors include Cormedix, Prime Medicine, Aclaris Therapeutics, Zevra Therapeutics, Supriya Lifescience, Luzhu Biotech, Sutro Biopharma, TTY Biopharm, Tempo Scan Pacific, Abclon.
What is the current market cap of Ocugen?Ocugen's current market cap is $609M.
What is the current revenue of Ocugen?Ocugen's last 12 months revenue is $3M.
What is the current revenue growth of Ocugen?Ocugen revenue growth (NTM/LTM) is 333%.
What is the current EV/Revenue multiple of Ocugen?Current revenue multiple of Ocugen is 178.5x.
Is Ocugen profitable?No, Ocugen is not profitable.
What is the current net income of Ocugen?Ocugen's last 12 months net income is ($69M).
How many companies Ocugen has acquired to date?As of May 2026, Ocugen has acquired 1 company.
What was the largest acquisition by Ocugen?None of the M&A deals Ocugen has completed have disclosed valuations.
What companies Ocugen acquired?Ocugen acquired Histogenics.
In how many companies Ocugen has invested to date?Ocugen hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to Ocugen

Lists including Ocugen

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial